Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis
Thoracic Cancer ( IF 2.9 ) Pub Date : 2024-03-26 , DOI: 10.1111/1759-7714.15291
Yao Zhang _{1,

2} , Huiting Li ₃ , Bo Yu _{1,

2} , Si Sun _{1,

2} , Zhihuang Hu _{1,

2} , Xianghua Wu _{1,

2} , Yang Zhang ₄ , Bin Li ₄ , Yawei Zhang ₄ , Jiaqing Xiang ₄ , Jialei Wang _{1,

2} , Hui Yu _{1,

2}

Affiliation

Neoadjuvant chemoimmunotherapy (NCIT) for locally advanced esophageal squamous cell carcinoma (ESCC) is supported by increasing data, but the sample size is limited, and the findings are not completely consistent. We conducted a real-world study and a meta-analysis to evaluate the efficacy and safety of NCIT in locally advanced ESCC.

中文翻译：

局部晚期食管鳞状细胞癌的新辅助化学免疫治疗：来自文献综述和现实世界分析的数据

新辅助化学免疫治疗（NCIT）治疗局部晚期食管鳞状细胞癌（ESCC）得到了越来越多数据的支持，但样本量有限，研究结果并不完全一致。我们进行了一项真实世界研究和荟萃分析，以评估 NCIT 在局部晚期 ESCC 中的有效性和安全性。

更新日期：2024-03-26

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>